← Leaderboards
Priyabrata Mukherjee
University Of Oklahoma Hlth Sciences Ctr
$10,375,168
Attributed
$13,049,624
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,049,624 · 8
By mechanism
R01$13,049,624 · 8
Top collaborators
- Resham Bhattacharya15 shared
Most similar at University Of Oklahoma Hlth Sciences Ctr
Same institution · by research overlap
- Resham Bhattacharya$4,398,302
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoTumor GrowthIn VitroGoldPropertyToxic EffectNeoplasm MetastasisMalignant NeoplasmsCellsTumorBaseCancer CellExhibitsPathway InteractionsMouse ModelBiodistributionPlayMolecularTreatment EfficacyMigrationSchemeOverexpressionProteinsSignal Transduction
Grant awards (43)
Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery system$367,289
R01 · FY2025 · CA · contact PI
Exploiting gold nanoparticle as a probe to identify therapeutic targets$354,959
R01 · FY2025 · CA · contact PI
Protein-nanoparticle interaction to study multicellular crosstalk within ovarian tumor microenviroment$326,103
R01 · FY2025 · CA · contact PI
Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery system$346,423
R01 · FY2024 · CA · contact PI
Exploiting gold nanoparticle as a probe to identify therapeutic targets$78,953
R01 · FY2024 · CA · contact PI
Exploiting gold nanoparticle as a probe to identify therapeutic targets$379,984
R01 · FY2023 · CA · contact PI
Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery system$376,116
R01 · FY2023 · CA · contact PI
Exploiting gold nanoparticle as a probe to identify therapeutic targets$398,989
R01 · FY2022 · CA · contact PI
UBAP2, A New Molecule in Pancreatic Cancer Progression$325,054
R01 · FY2022 · CA · contact PI
Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery system$310,077
R01 · FY2022 · CA · contact PI
Reprogramming Tumor Microenvironment by Nanoparticle$338,550
R01 · FY2021 · CA · contact PI
UBAP2, A New Molecule in Pancreatic Cancer Progression$331,688
R01 · FY2021 · CA · contact PI
Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery system$316,405
R01 · FY2021 · CA · contact PI
Reprogramming Tumor Microenvironment by Nanoparticle$338,550
R01 · FY2020 · CA · contact PI
UBAP2, A New Molecule in Pancreatic Cancer Progression$331,688
R01 · FY2020 · CA · contact PI
Molecular Mechanism of Antiangiogenic Properties of Gold Nanoparticle$304,695
R01 · FY2020 · CA · contact PI
Reprogramming Tumor Microenvironment by Nanoparticle$328,393
R01 · FY2019 · CA · contact PI
UBAP2, A New Molecule in Pancreatic Cancer Progression$321,736
R01 · FY2019 · CA · contact PI
Molecular Mechanism of Antiangiogenic Properties of Gold Nanoparticle$295,553
R01 · FY2019 · CA · contact PI
Reprogramming Tumor Microenvironment by Nanoparticle$338,550
R01 · FY2018 · CA · contact PI
UBAP2, A New Molecule in Pancreatic Cancer Progression$331,688
R01 · FY2018 · CA · contact PI
Molecular Mechanism of Antiangiogenic Properties of Gold Nanoparticle$304,695
R01 · FY2018 · CA · contact PI
Cystathionine beta synthase (CBS) and angiogenesis$421,311
R01 · FY2017 · HL · contact PI
Reprogramming Tumor Microenvironment by Nanoparticle$338,550
R01 · FY2017 · CA · contact PI
Molecular Mechanism of Antiangiogenic Properties of Gold Nanoparticle$304,695
R01 · FY2017 · CA · contact PI
Cystathionine beta synthase (CBS) and angiogenesis$422,373
R01 · FY2016 · HL · contact PI
Molecular Mechanism of Antiangiogenic Properties of Gold Nanoparticle$188,191
R01 · FY2016 · CA · contact PI
Molecular Mechanism of Antiangiogenic Properties of Gold Nanoparticle$116,504
R01 · FY2016 · CA · contact PI
Cystathionine beta synthase (CBS) and angiogenesis$417,052
R01 · FY2015 · HL · contact PI
Cystathionine beta synthase (CBS) and angiogenesis$415,917
R01 · FY2014 · HL · contact PI
Cystathionine beta synthase (CBS) and angiogenesis$416,962
R01 · FY2013 · HL · contact PI
Molecular mechanism of antiangiogenic properties of gold nanoparticle$249,006
R01 · FY2013 · CA · contact PI
Development of a gold nanoparticles based targeted delivery system$233,048
R01 · FY2013 · CA · contact PI
Development of a gold nanoparticles based targeted delivery system$45,693
R01 · FY2013 · CA · contact PI
Molecular mechanism of antiangiogenic properties of gold nanoparticle$8,285
R01 · FY2013 · CA · contact PI
Development of a gold nanoparticles based targeted delivery system$304,127
R01 · FY2012 · CA · contact PI
Molecular mechanism of antiangiogenic properties of gold nanoparticle$273,714
R01 · FY2012 · CA · contact PI
Development of a gold nanoparticles based targeted delivery system$304,127
R01 · FY2011 · CA · contact PI
Molecular mechanism of antiangiogenic properties of gold nanoparticle$273,714
R01 · FY2011 · CA · contact PI
Development of a gold nanoparticles based targeted delivery system$313,533
R01 · FY2010 · CA · contact PI
Molecular mechanism of antiangiogenic properties of gold nanoparticle$282,179
R01 · FY2010 · CA · contact PI
Development of a gold nanoparticles based targeted delivery system$292,326
R01 · FY2009 · CA · contact PI
Molecular mechanism of antiangiogenic properties of gold nanoparticle$282,179
R01 · FY2009 · CA · contact PI